Theresa LaVallee, Coherus's Chief Development Officer, joined Joni L Rutter, Laurence Sperling, and peter stein to discuss the Future of R&D in drug development in a panel moderated by Fierce Pharma editor Conor Hale at the Milken Institute 2024 Future of Health Summit. Listen to the discussion here: https://lnkd.in/e2s78cTn #MIHealthSummit
Coherus BioSciences
生物技术研究
Redwood City，CA 35,070 位关注者
We are in the business of extending life for patients.
关于我们
Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. We are building a leading oncology company backed by in-house expertise and an established infrastructure from our diversified portfolio of FDA-approved biosimilar products. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at https://www.coherus.com/careers/ for a list of career opportunities.
- 网站
-
https://www.coherus.com
Coherus BioSciences的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- Redwood City，CA
- 类型
- 上市公司
- 创立
- 2010
- 领域
- biotechnology、biosimilars和Immuno-oncology
地点
Coherus BioSciences员工
动态
-
Today, we’re honoring all those who have served our country. Thank you for your bravery. #VeteransDay?
-
-
Don’t miss our presentation today at SITC 2024 on CHS-114, an anti-CCR8 cytolytic monoclonal antibody that preferentially depletes intratumoral Tregs and induces antitumor immune responses. View our poster https://bit.ly/3YaEEEg #oncology?#CCR8
-
-
Attending SITC 2024? Stop by our presentation today to learn more about Casdozokitug, a first-in-class, anti-IL27 antagonistic antibody treatment and its potential to promote NK and T cell driven antitumor response in a Phase I study in patients with advanced solid tumors. View the poster: https://bit.ly/3XUGZSH #oncology
-
-
Join us for our Q3 2024 earnings call today, starting at 5:00 pm ET, to hear about our Q3 financial results and recent business highlights. Press release: https://bit.ly/3ChZ465 Listen to the webcast: https://bit.ly/4e9J1UU
-
-
Coherus will report Q3 2024 financial results on November 6, 2024. Starting at 5 pm EDT, CEO Denny Lanfear and the executive team will host a conference call and webcast to discuss Q3 2024 financial results and recent business highlights. Webcast link: https://bit.ly/4e9J1UU
-
-
Attending Cytokines 2024-KAI 2024? Meet with Theresa LaVallee, our Chief Development Officer, to learn more about our IL-27 antagonist, casdozokitug. Dr. LaVallee will present data for casdozokitug (abstract P2-CI096) during the cancer immunology and immunotherapy?poster session on October 21st in Poster Area 3.?
-
-
Congratulations to Coherus Board Member?Jill O'Donnell-Tormey?for being honored at the Cancer Research Institute (CRI) Annual Awards Gala! Dr. O'Donnell-Tormey has been awarded the 2024 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research. We’re proud to have her leadership and support as a valued member of our board. #leadership #biotech #oncology?
-
-
Congratulations to our Chief Development Officer, Dr. Theresa LaVallee, for being recognized by Endpoints News as one of the top 20 women breaking barriers in drug development and inspiring the next generation of leaders. Join us in celebrating all the honorees at ENDPOINTS’ virtual event on October 8th at 11am ET. #biotech #leadership #oncology Register here: https://bit.ly/3Zmn8hy
-
-
Coherus is heading to Houston for the Society for Immunotherapy of Cancer (SITC) 2024! Our team is excited to be presenting data on casdozokitug, a first-in-class, anti-IL27 antagonistic antibody treatment promoting NK and T cell driven antitumor response in a Phase I study in patients with advanced solid tumors, and CHS-114, an anti-CCR8 cytolytic monoclonal antibody that preferentially depletes intratumoral Tregs and induces antitumor immune responses. #oncology
-